Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for S1R from our risk checks.
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥1.33 |
52 Week High | CN¥1.90 |
52 Week Low | CN¥1.20 |
Beta | 0.25 |
1 Month Change | -10.14% |
3 Month Change | 7.26% |
1 Year Change | -23.12% |
3 Year Change | -20.36% |
5 Year Change | -31.79% |
Change since IPO | -24.00% |
Recent News & Updates
Recent updates
Shareholder Returns
S1R | DE Healthcare | DE Market | |
---|---|---|---|
7D | -1.5% | -3.2% | 1.9% |
1Y | -23.1% | -1.8% | 7.3% |
Return vs Industry: S1R underperformed the German Healthcare industry which returned -2.3% over the past year.
Return vs Market: S1R underperformed the German Market which returned 6.4% over the past year.
Price Volatility
S1R volatility | |
---|---|
S1R Average Weekly Movement | 5.0% |
Healthcare Industry Average Movement | 5.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S1R has not had significant price volatility in the past 3 months.
Volatility Over Time: S1R's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 47,811 | Bo Shen | https://www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including anti-tumor, heart and cerebral vessels, psychoneural, anti-infection, auto-immunity, digestive tract and metabolism, and respiratory system.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
S1R fundamental statistics | |
---|---|
Market cap | €7.30b |
Earnings (TTM) | €588.43m |
Revenue (TTM) | €32.60b |
13.7x
P/E Ratio0.2x
P/S RatioIs S1R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
S1R income statement (TTM) | |
---|---|
Revenue | CN¥254.88b |
Cost of Revenue | CN¥223.22b |
Gross Profit | CN¥31.66b |
Other Expenses | CN¥27.06b |
Earnings | CN¥4.60b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | 1.24 |
Gross Margin | 12.42% |
Net Profit Margin | 1.80% |
Debt/Equity Ratio | 64.5% |
How did S1R perform over the long term?
See historical performance and comparison